MTCP1 and B-cell chronic lymphocytic leukemia: Finally, immune competent mice engrafted with CLL-like cells of Eμ-MTCP1 over-expressing mice and treated with VIP152 demonstrated reduced disease burden and improvement in overall survival compared to vehicle-treated mice.